Literature DB >> 1671606

Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol.

I Ringel1, S B Horwitz.   

Abstract

RP 56976 (taxotere), a new semisynthetic analogue of taxol, is a potentially important chemotherapeutic agent for the treatment of cancer. We report here that this drug is a potent inhibitor of cell replication and, like taxol, promotes the in vitro assembly of stable microtubules in the absence of guanosine triphosphate and induces microtubule-bundle formation in cells. Compared with taxol, RP 56976 is slightly more active as a promoter of tubulin polymerization. As an inhibitor of cell replication, RP 56976 is 2.5-fold more potent than taxol in J774.2 and P388 cells and at least 5-fold more potent in taxol-resistant cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1671606     DOI: 10.1093/jnci/83.4.288

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  133 in total

Review 1.  Chemotherapy in non-small cell lung cancer.

Authors:  C J Sweeney; A B Sandler
Journal:  Invest New Drugs       Date:  2000-05       Impact factor: 3.850

Review 2.  Advanced non-small cell lung carcinoma: the emerging role of docetaxel.

Authors:  C J Langer
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

Review 3.  Docetaxel: a review of its use in non-small cell lung cancer.

Authors:  A M Comer; K L Goa
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

4.  Interstitial docetaxel (taxotere), carmustine and combined interstitial therapy: a novel treatment for experimental malignant glioma.

Authors:  Prakash Sampath; Laurence D Rhines; Francesco DiMeco; Betty M Tyler; Michael C Park; Henry Brem
Journal:  J Neurooncol       Date:  2006-04-25       Impact factor: 4.130

5.  Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan.

Authors:  Kazuo Nishimura; Norio Nonomura; Katsuyoshi Hashine; Hiro-Omi Kanayama; Seiichiro Ozono; Takeshi Miura; Tsuneharu Miki; Yoshiyuki Kakehi; Yoichi Arai; Osamu Ogawa; Ryuji Fujita; Katsuya Nonomura; Atsushi Mizokami; Senji Hoshi; Hideyuki Akaza
Journal:  Int J Clin Oncol       Date:  2012-02-21       Impact factor: 3.402

6.  Phase I/II docetaxel plus concurrent hyperfractionated radiotherapy in locally advanced unresectable head and neck cancer (TAX.ES1.102 study).

Authors:  Agustí Barnadas; Ricard Mesía; Margarita Majem; Ramón Galiana; Antonio López-Pousa; José M de Vega; Mireia Margelí; Vicente Valentí; Lluís Anglada; Ariadna Lloansí; Antonio Arellano
Journal:  Clin Transl Oncol       Date:  2011-04       Impact factor: 3.405

7.  A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer.

Authors:  Taisuke Mori; Kenichi Hosokawa; Yoshiyuki Kinoshita; Ai Watanabe; Takeshi Yamaguchi; Haruo Kuroboshi; Yoshiko Kato; Jinsuke Yasuda; Hiroyuki Fujita; Yoshinori Nakata; Hideo Honjo
Journal:  Int J Clin Oncol       Date:  2007-06-27       Impact factor: 3.402

Review 8.  CNS complications of breast cancer: current and emerging treatment options.

Authors:  Evert C A Kaal; Charles J Vecht
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

9.  Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel.

Authors:  Y Fromes; P Gounon; R Veitia; M C Bissery; A Fellous
Journal:  J Protein Chem       Date:  1996-05

10.  Chromatin Regulators as a Guide for Cancer Treatment Choice.

Authors:  Zachary A Gurard-Levin; Laurence O W Wilson; Vera Pancaldi; Sophie Postel-Vinay; Fabricio G Sousa; Cecile Reyes; Elisabetta Marangoni; David Gentien; Alfonso Valencia; Yves Pommier; Paul Cottu; Geneviève Almouzni
Journal:  Mol Cancer Ther       Date:  2016-05-16       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.